This study looks at the effects of weight loss in people who have heart failure with reduced ejection fraction (HFpEF) and are overweight or obese. The main questions it aims to answer are whether weight loss in this group of people improves: * The heart's shape and how well it pumps blood * The person's quality of life and how much they can exercise Participants will attend 2 study visits, separated by 3-6 months. The intervention period takes place in between the 2 study visits. Each study visit may involve measurements including: Symptom and quality of life questionnaires Body measurements such as height and weight Blood tests Ultrasound scans of the heart (echocardiogram) Magnetic Resonance Imaging (MRI) scans of the heart 6 minute walk test Participants are randomly allocated (in other words, by lottery) to either 'diet' or 'control' groups. The control group will continue standard care. The diet group will be enrolled in a weight loss program supervised by the study team. Participants in the diet group will replace their usual meals with meal replacement products specifically designed to deliver a low calorie diet for weight loss. The products will consist of formula soups, shakes and porridges. This diet would last 8 weeks, followed by a guided period of food reintroduction and maintenance.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
110
The diet intervention delivers a weight loss program. The main component is a total diet replacement low energy diet. The intervention includes a gradual food reintroduction phase and maintenance strategies.
Jersey General Hospital
Jersey, Jersey, Jersey
RECRUITINGJenny Rayner
Oxford, United Kingdom
RECRUITINGLeft ventricular ejection fraction
On cardiac magnetic resonance imaging (CMR)
Time frame: Change from baseline at 3-6 months
Body weight
Time frame: Change from baseline at 3-6 months
Six minute walk distance
Time frame: Change from baseline at 3-6 months
Kansas City Cardiomyopathy Questionnaire (KCCQ)
A scale of 0 - 100, where higher scores indicate better outcomes.
Time frame: Change from baseline at 3-6 months
N-terminal pro brain natriuretic peptide (NTproBNP)
Time frame: Change from baseline at 3-6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.